Xencor (XNCR)
(Delayed Data from NSDQ)
$23.03 USD
+0.57 (2.54%)
Updated May 17, 2024 04:00 PM ET
After-Market: $23.02 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
Xencor, Inc. [XNCR]
Reports for Purchase
Showing records 81 - 100 ( 216 total )
Company: Xencor, Inc.
Industry: Medical - Drugs
Hem-Onc Physician Survey: XPOVIO, TAZVERIK, and Tafasitamab Insights
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
EHA 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
CORRECTED AACR 2020 Titles for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Biotechnology- From Underneath the Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Xencor, Inc.
Industry: Medical - Drugs
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D